GlassScriptPhysician profile
Sandeep Magoon
NPI 1962698720
$203,924.35
in general payments reported to CMS, 2019-2025
24 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $134 · 2021: $5,804 · 2022: $74K · 2023: $56K · 2024: $52K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $64K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $12K · Consulting Fee: $4,814 · Food and Beverage: $4,056 · Education: $97.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $64,026.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,967.50 |
| Travel and Lodging | $11,920.06 |
| Consulting Fee | $4,814.40 |
| Food and Beverage | $4,055.53 |
| Education | $97.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $122,840.15 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $72,376.84 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,986.16 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $617.55 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $399.83 | 2019-2025 | |
| Travere Therapeutics, INC. | $184.52 | 2023-2025 | Filspari |
| Nxstage Medical, INC. | $177.14 | 2019-2022 | |
| Ardelyx, INC. | $148.05 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $142.63 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $137.44 | 2019-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $134.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.04 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $132.19 | 2022-2023 | Ultomiris |
| Bard Peripheral Vascular, INC. | $117.05 | 2025 | |
| Amgen INC. | $110.56 | 2024-2025 | Tavneos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $72.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $56.34 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $49.89 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $27.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.76 | 2021 | |
| Fresenius USA Marketing, INC. | $18.87 | 2019 | |
| Baxter Healthcare | $15.80 | 2022 | |
| Glaxosmithkline, LLC. | $13.52 | 2022 | |
| Horizon Therapeutics Plc | $12.72 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Magoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.